Longevity Thrive
update
Longevity Thrive
Thriving Health For Thriving Life
update
  • Home
  • Categories
    • Cell Renewal
    • Telomere Science
    • Supplement Guide
    • Diet Protocols
    • Expert Insights
    • Biohacking Tips
    • Research Updates
November 10.2026
2 Minutes Read

Unlocking Longevity: How Vanadyl Sulfate Can Extend Life and Boost Health

Vivid cell illustration in abstract background, latest aging research theme

The Impact of Vanadyl Sulfate on Lifespan and Healthspan

Recent research has unveiled promising findings regarding vanadyl sulfate (VS), a naturally occurring mineral that shows potential in rejuvenating aging cells. This study from the University of Chicago's researchers highlights significant improvements in both the lifespan and healthspan of older male mice after just a brief exposure to VS. With the increasing interest in longevity and anti-aging supplements, these results might provide new avenues for enhancing our health as we age.

Understanding Senescence: The New Anti-Aging Frontier

Senescent cells, often dubbed "zombie cells," are those that have lost their ability to divide but are not dead. They can cause inflammation and tissue damage, contributing significantly to aging and age-related diseases. Vanadyl sulfate acts as a senolytic agent, meaning it specifically targets and eliminates these dysfunctional cells, promoting healthier tissue and cellular function. Understanding this mechanism is crucial, as it offers insights into the cellular biology of aging and potential interventions for longevity.

Potential Mechanisms Behind VS’s Effectiveness

The intriguing aspect of VS is its selective action on senescent cells. The compound seems to exploit certain vulnerabilities within these aged cells, leading to their controlled self-destruction—a process known as apoptosis. More precisely, the study found that VS disrupts the handling of proteins within senescent cells, causing them to accumulate improperly folded proteins that trigger their demise.

Gender Differences in Longevity Research

It's essential to highlight the subtle differences between male and female reactions to treatments like VS. While male mice showed a marked increase in lifespan and biological improvements, the study's authors did not investigate female lifespan outcomes. This opens the door to further research into gender-specific responses in aging and treatments. Such nuances are crucial for developing tailored anti-aging therapies.

Implications for Human Health and Aging

The benefits observed in mice hold significant implications for human health, particularly as more individuals seek ways to enhance their longevity. The ability to combat age-related decline through dietary supplements presents an exciting avenue for achieving healthier aging. However, it is important to remember that while these results are promising, human clinical trials will be necessary to understand the full range of outcomes and potential side effects.

Broader Perspectives on Longevity Science

The quest for longevity often involves a combination of lifestyle changes, dietary measures, and the integration of innovative supplements. As longevity science continues to evolve, findings like those surrounding vanadyl sulfate encourage individuals to explore various facets of health, from exercise to nutrition, that can contribute to a longer, healthier life. The future of aging research appears bright, and keeping an eye on emerging breakthroughs can empower individuals to make informed choices.

As we explore these scientific advances in aging, we ignite discussions around the potentials of supplements like vanadyl sulfate. Stay engaged with the latest findings and trends in longevity science to enhance your well-being.

Research Updates

0 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
11.07.2026

Unlocking the Secrets: NOVOS Core and Its Impact on Vascular Health

Update Exploring the Impact of NOVOS Core on Vascular Health A recent clinical trial has brought exciting news in the field of longevity. The supplement NOVOS Core has been associated with significant improvements in artery function and systolic blood pressure, as led by Professor Christian Heiss at the University of Surrey. Published in the European Heart Journal Open, the trial highlights the potential of this supplement in promoting cardiovascular health, particularly as our understanding of the biology of aging continues to evolve. Why Artery Function Matters Our arteries play a critical role in maintaining overall health; they are responsible for carrying oxygen-rich blood from the heart to various parts of the body. With age, arteries tend to become less flexible and responsive, which can lead to various cardiovascular issues, including high blood pressure. The NOVOS Core supplement aims to address these age-related changes by incorporating ingredients believed to combat several biological processes of aging. Decoding the Ingredients NOVOS Core presents a multi-ingredient formula that includes glycine, calcium alpha-ketoglutarate, and L-theanine, among others. Each of these components is chosen based on prior research, with the intention of working synergistically to enhance various aspects of vascular health. However, during the trial, it was the whole formula that was evaluated, making it unclear which specific ingredients were primarily responsible for the observed improvements. Trial Insights: The Numbers Tell a Story The study involved 61 participants who were divided into groups receiving either NOVOS Core or a placebo. After six months, participants taking the supplement demonstrated a significant improvement in flow-mediated dilation (FMD)—a measure of how well the arteries expand when blood flow increases—rising by an average of 2.6 percentage points. Also, systolic blood pressure decreased by 8.5 mmHg, contributing to an overall better cardiovascular risk profile. The Importance of Methodology While the results indicate promising benefits, the study's design included a substantial concern—attrition of participants from the trial. With nearly a third of individuals lost to follow-up, any conclusions drawn must be approached cautiously. Moreover, the differing average ages of the supplement and placebo groups (60 vs. 53 years) raises additional questions about the results’ implications, particularly concerning age-related vascular changes. Expert Opinions Add Context Experts in the field are enthusiastic but cautious. Dr. Brad Stanfield, a physician focused on longevity, reflected on the findings by noting the impressive numbers, especially the increase in FMD. However, he also highlighted the necessity for more robust studies to verify these findings due to the study’s limitations and potential confounding variables. As researchers continue to explore the mechanisms behind these age-related changes, the insights gained from trials like the one involving NOVOS Core provide an essential look into how we might enhance our healthspan. Indeed, the ongoing investigation into the biology of aging promises to uncover more breakthroughs that can help us age gracefully. Stay Informed on Longevity Science The advancements in longevity supplements, such as NOVOS Core, represent just a fraction of the exciting developments in healthspan research. For those keen on anti-aging breakthroughs and the latest findings in aging, staying informed is critical as science continues to unfold new opportunities for enhancing vitality.

11.06.2026

Positive Shifts in Longevity Regulation and Investment Strategies

Update Exciting Developments in Longevity Science April 2023 marks a pivotal moment for rejuvenation biotechnology, with significant momentum building on two critical fronts: regulatory advancements and investment strategies. For years, those invested in the longevity sector have grappled with slow-moving regulatory processes and a capital environment clouded by hype rather than scientific rigor. Fortunately, new developments suggest that change is on the horizon. The Regulatory Environment: Shifting Towards Innovation A key indicator of progress comes from the FDA, which recently identified longevity as a priority during the Aging Research and Drug Discovery (ARDD) meeting in Boston. Leaders from the agency emphasized the need for regulatory science to adapt to the complexities of aging biology, leaving behind outdated notions of whether aging should be classified as a disease. Harvard researcher Vadim Gladyshev aptly posits that aging represents the cumulative biological backdrop fostering various age-related diseases rather than a clear-cut pathology. This nuanced understanding paves the way for designing regulatory pathways that truly address aging biology. A whitepaper recently published by the Lifespan Research Institute argues that the barriers to progress are institutional rather than solely biological. Adaptations such as platform technology designations and validated surrogate endpoints could streamline the pathway for interventions targeting aging in various contexts, thus maximizing their health and economic benefits. Capitalizing on the Longevity Dividend Alongside regulatory shifts, the economic implications of accessibility in biomedical technologies have been highlighted as crucial. Our article on democratizing rejuvenation emphasizes that limiting access to biomedical repair technologies could engender substantial social and economic costs. As the concept of the Longevity Dividend - the positive outcomes gained from extending healthy productive years - gains traction, it's evident that equitable access is essential to maximize these benefits. This isn't merely a matter of fairness; it’s vital for broader economic productivity. Exciting Clinical Trials and Initial Results An encouraging development to note is the announcement from Life Biosciences regarding their first human trial data from a gene therapy aimed at glaucoma patients: ER-100. Initial Phase 1 results reveal promising tolerability in participants and positive early indicators of visual improvements. It is crucial to acknowledge that while these findings are early-stage, they provide a stark contrast to unchecked supplement claims outside of regulatory frameworks. Investment Landscape: Mainstreaming Longevity In terms of investment, the importance of recognizing longevity as a growing market has also become increasingly evident. Discussions among investment leaders, such as the recent Investing Unlocked segment, underscore how the concept of longer healthy lives is now factoring into economic forecasts. Moving the conversation around longevity away from speculative biotech to more grounded economic variables is an encouraging sign that norms around funding in this sector are shifting. Connecting Science with Investment The Longevity Investor Network, where I serve alongside committed professionals, aims to directly link serious science with responsible investors. We are excited to announce two upcoming events: the Longevity Biotech Pitch Night in New York and the Longevity Biotech Pitch Day in San Francisco during JPM week. These gatherings will foster connections between innovative companies and discerning investors, highlighting the crucial difference between promising biological strategies and speculative hype. What Lies Ahead in Longevity? Overall, these trends signal an optimistic future for longevity research and biotechnology. While we need to navigate complex biological challenges and understand timelines that extend over years, the evolving regulatory landscape and the increasing comfort of mainstream investment in this space will enable us to work towards more sustainable and meaningful advancements. For an emerging field such as this, building an institutional framework that supports advancements in longevity is a crucial factor for progress. Join our mission! As a non-profit focused on innovation in aging research, we invite you to support independent journalism and drive conversations that pave the way for longer, healthier lives. Your contribution, whatever the size, helps sustain research and keep our informative content widely accessible. Thank you for being part of this exciting journey toward rejuvenation and longevity.

11.04.2026

Discover How Male Mice Lose Anti-Cancer Immunity Earlier: Key Insights

Update Understanding the Immune System's Aging Process As we age, our immune system undergoes notable transformations. A recent study from Massachusetts General Hospital sheds light on why male mice lose their cancer-fighting capabilities more quickly than female mice. This research highlights the shrinking reserves of naive T cells, which are crucial for identifying and combating tumors. An important consideration is that the decline in naive T cell numbers initiates earlier in males, potentially leading to higher cancer incidences observed around middle age. Why Male Mice Struggle More with Cancer In laboratory experiments, it was found that when melanoma was implanted into young and middle-aged mice, young males and females exhibited similar tumor growth rates. However, middle-aged males showed reduced effectiveness in controlling tumor growth when compared to their female counterparts. The presence of more tumor-specific CD8+ T cells in middle-aged females played a significant role in their superior anti-tumor response, demonstrating potential differences in immunological aging between the sexes. Role of Lymph Nodes in Immune Response Interestingly, when researchers further explored the underlying reasons for these differences, they focused on lymph nodes, essential components of the immune system that help activate T cells against antigens. The results showed that the lymph nodes of middle-aged female mice were more capable of harboring activated CD8+ T cells, whereas male mice exhibited earlier reductions in both lymph node size and naive T cell populations. These findings suggest that preserving lymph node function could be vital for maintaining immune defenses as we age. Virtual Memory Cells and Their Implications The study also highlighted an intriguing phenomenon known as “virtual memory cells.” While these cells can respond to threats, they arise from naive T cells that have not encountered their specific antigen. Notably, male mice displayed an early bias towards these virtual memory cells which, although rapidly expand when activated, do not match the efficiency of traditional memory T cells. This transition can potentially weaken the anti-cancer response in older males. The Thymus and Aging: A Closer Look The role of the thymus is another critical element of this research. This organ is responsible for the maturation of T cells, and its size decreases with age—a process known as thymic involution. Males experience this shift more rapidly than females, correlating with a decline in naive T cell count. The research suggests that enhancing thymic function in older males could be a viable strategy for improving their immune responses against tumors. Potential Solutions and Future Implications The findings from this study are crucial, not just within the scope of laboratory research but also for potential clinical applications. Researchers observed that reducing androgen levels, such as testosterone, could significantly enhance naive T cell numbers and bolster tumor-specific responses. This presents an exciting potential for therapeutics targeting demographic disparities in cancer prevalence. As we explore these insights, it becomes increasingly clear that understanding the unique differences between male and female immune responses offers avenues for advancing cancer prevention strategies. Further studies in this area may offer significant recommendations for enhancing longevity and healthspans. Consider supporting our ongoing research and articles like this one for everyone by donating. Every contribution, no matter the amount, helps us sustain high-quality, independent journalism.

cropper
update
Longevity Thrive
cropper
update

Longevity Thrive empowers individuals with science-backed insights, expert advice, and practical tools to optimize health, wellness, and longevity.

  • update
  • update
  • update
  • update
  • update
  • update
  • update
UPDATE

ABOUT US

Longevity Thrive is a media platform dedicated to providing science-backed insights, practical strategies, and the latest trends in health, wellness, and longevity. It empowers individuals to optimize their healthspan and live vibrant, fulfilling lives.

© 2026 Longevity Thrive All Rights Reserved. Harp Island Close, London, Brent NW100DF . Contact Us . Terms of Service . Privacy Policy

{"company":"Longevity Thrive","address":"Harp Island Close","city":"London","state":"Brent","zip":"NW100DF","email":"lorenas@getmilerismarketing.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*